Who
Tamara A. Favorito
Director
Company insider
Files Form 4 as: Director, Artelo Biosciences; Director, Zevra Therapeutics; Director, TuHURA Biosciences; CFO, Secretary, Treasurer, Viridian Therapeutics; Chief Financial Officer, Favrille.
In numbers
- Trades disclosed
- 70
- Buys
- 3
- Sells
- 1
- Bought
- $28K
- Sold
- $100
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 7 Feb 2005
- Last trade
- 17 Jul 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —136 at $0.00 | filing |
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 4 Jun 2026filed 18 Jun 2026 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 30 Jan 2026filed 2 Feb 2026 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —292 at $0.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | $171.2M6,846 at $25,000.00 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | —12,566 | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | — | filing |
| 28 Oct 2025filed 30 Oct 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code C | — | filing |
| 12 Sep 2025filed 16 Sep 2025 | ZVRA Zevra TherapeuticsBiotechnology | SEC FORM 4 Bought | $25K3,175 at $7.79 | filing |
| 29 May 2025filed 30 May 2025 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 1 May 2025filed 5 May 2025 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code P | — | filing |
| 20 Dec 2024filed 23 Dec 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,750 at $0.00 | filing |
| 13 May 2024filed 15 May 2024 | ZVRA Zevra Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —49,200 at $0.00 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —2,000 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —667 | filing |
| 28 Feb 2024filed 1 Mar 2024 | ARTL Artelo Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,083 | filing |
News
No headline names them, or the companies they trade most, lately.